Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILD-24-01
2024-515672-12-00Phase 3Authorised
- Sponsor
- Sun Pharma
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in psoriasis and plaque psoriasis comparing Tildrakizumab with Placebo (2 arms). Primary endpoint: Primary: Genital modified sPGA-G response at week 16. Planned start May 2025; status: authorised.
02
Drugs
tildrakizumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2024-515672-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515672-12-00.